Logo

IKT

Inhibikase Therapeutics, Inc.

IKT

Inhibikase Therapeutics, Inc. • NASDAQ
$1.52 ▼ -1.30% (-0.02)
Market Cap $114.22 M
52w High $4.20
52w Low $1.33
Dividend Yield 0%
P/E 3.23
Volume 181.04K
Outstanding Shares 75.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $13.238M ▲ $-11.93M ▼ 0% $-0.133 ▼ $-11.907M ▼
Q2-2025 $0 $10.832M ▼ $-9.916M ▲ 0% $-0.11 ▲ $-11.167M ▲
Q1-2025 $0 $14.598M ▲ $-13.679M ▼ 0% $-0.15 ▲ $-15.75M ▼
Q4-2024 $0 $12.922M ▲ $-12.133M ▼ 0% $-0.17 ▲ $-12.126M ▼
Q3-2024 $0 $5.827M $-5.778M 0% $-0.65 $-5.821M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $77.322M ▼ $79.595M ▼ $6.696M ▼ $72.898M ▼
Q2-2025 $87.666M ▼ $88.853M ▼ $8.8M ▲ $80.054M ▼
Q1-2025 $93.18M ▼ $94.281M ▼ $8.551M ▲ $85.731M ▼
Q4-2024 $97.544M ▲ $98.6M ▲ $3.734M ▼ $94.866M ▲
Q3-2024 $3.244M $4.377M $4.907M $-530.591K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.93M ▼ $-10.593M ▼ $-28.746M ▼ $-134.13K ▼ $-39.473M ▼ $-10.593M ▼
Q2-2025 $-9.916M ▲ $-5.574M ▼ $9.844M ▼ $31.771K ▲ $4.301M ▼ $-5.574M ▼
Q1-2025 $-13.679M ▼ $-4.104M ▲ $21.054M ▲ $0 ▼ $16.951M ▼ $-4.104M ▲
Q4-2024 $-12.133M ▼ $-5.346M ▼ $-38.762M ▼ $99.684M ▲ $55.577M ▲ $-5.346M ▼
Q3-2024 $-5.778M $-4.881M $2.526M $181.954K $-2.173M $-4.881M

Five-Year Company Overview

Income Statement

Income Statement Inhibikase is a classic early-stage biotech story: it has no product revenue yet, so the income statement is entirely driven by research and development and overhead costs. The company has reported steady losses each year, reflecting ongoing investment in clinical trials and platform development. The loss levels look controlled rather than explosive, suggesting a disciplined spend, but profitability is entirely dependent on successful approvals and eventual commercialization, which are still in the future.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. Historically, assets have largely consisted of cash, with very little in the way of physical assets and no financial debt. Equity is positive, which means the company has not overleveraged itself. More recent disclosures point to a much stronger cash position following financing, giving it a longer runway to fund trials. The main risk is that, as a pre-revenue biotech, the balance sheet will remain dependent on external capital until a product reaches the market.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, as expected for a company funding clinical research with no commercial products. There is virtually no spending on heavy equipment or facilities, so cash use is mainly salaries, trials, and development costs. This means the company will likely continue to consume cash and rely on equity raises or partnerships to refill the tank. The current burn rate looks measured, but the timing and outcome of clinical milestones will heavily influence future funding needs.

Competitive Edge

Competitive Edge Competitively, Inhibikase is trying to differentiate itself in a crowded neurodegeneration and rare-disease space with a focused approach on c-Abl inhibition and its RAMP platform. Its lead Parkinson’s program aims to modify the course of disease, not just treat symptoms, which is a meaningful scientific ambition if it translates into humans. The PAH program, with potential orphan advantages, targets a narrower but more defined market. However, the company is up against larger players, other c-Abl efforts, and the usual high failure risk in neurology, so its current moat is based more on intellectual property, specialization, and early clinical data than on market presence.

Innovation and R&D

Innovation and R&D Innovation and R&D are clearly the heart of the story. The RAMP engine is designed to rework known kinase drugs into potentially safer, more potent versions, which can shorten learning curves compared with completely untested biology. The Parkinson’s candidate and the prodrug for PAH both build on well-understood mechanisms, but with new chemistry intended to improve brain penetration, safety, and tolerability. The pipeline is still concentrated in just a few main assets, so success or failure in those programs will drive most of the R&D value. Overall, this is a high-risk, high-reward research portfolio typical of a small, clinical-stage biotech.

Summary

Inhibikase is an early-stage biotech with no revenue, controlled but persistent losses, and a balance sheet that has been recently reinforced by fresh cash. The company’s value proposition rests on a specialized technology platform and a small number of lead programs targeting Parkinson’s disease and pulmonary arterial hypertension with a disease-modifying, kinase-focused strategy. Its strengths are scientific focus, a differentiated mechanism, intellectual property, and non-dilutive benefits like potential orphan status. Its main risks are binary clinical outcomes, ongoing cash burn, reliance on capital markets or partners, and competition from larger, better-funded companies working on similar diseases. The long-term outcome will depend heavily on upcoming clinical readouts and regulatory progress.

NEWS

November 20, 2025 · 9:54 PM UTC

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Read more

November 20, 2025 · 4:12 PM UTC

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Read more

November 20, 2025 · 4:01 PM UTC

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Read more

November 14, 2025 · 4:01 PM UTC

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Read more